Treatment of invasive infections due to rare or emerging yeasts and moulds.
Emerging fungal infections represent a serious problem in an immunocompromised host. Rapid developments in in vitro antifungal susceptibility testing and the availability of several new antifungal agents have provided excellent opportunities to treat infections that are caused by various Candida spp. and to some extend by Aspergillus spp. However, recently the epidemiology of fungal infections has significantly changed and several new pathogens have emerged. This article attempts to summarise the available data on the management of emerging infections with fungal infections that have recently gained importance. Updated recommendations on antifungal treatment are also discussed.
Sahin
Gulsen Ozkaya
GO
Hacettepe University School of Medicine, Section of Infectious Diseases, Ankara 06100, Turkey.
Akova
Murat
M
D000666:Amphotericin B / Q000008:administration & dosage / Q000627:therapeutic use; D000818:Animals; D000935:Antifungal Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001228:Aspergillosis / Q000188:drug therapy* / Q000276:immunology; D002177:Candidiasis / Q000188:drug therapy* / Q000276:immunology; D002986:Clinical Trials as Topic; D004334:Drug Administration Schedule; D025141:Drug Resistance, Fungal; D004359:Drug Therapy, Combination; D015725:Fluconazole / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D016867:Immunocompromised Host; D009091:Mucormycosis / Q000188:drug therapy* / Q000276:immunology; D017410:Practice Guidelines as Topic; D011743:Pyrimidines / Q000008:administration & dosage / Q000627:therapeutic use; D014230:Triazoles / Q000008:administration & dosage / Q000627:therapeutic use; D065819:Voriconazole
D000935:Antifungal Agents; D011743:Pyrimidines; D014230:Triazoles; D000666:Amphotericin B; D015725:Fluconazole; D065819:Voriconazole